New drug combo aims to stop stomach Cancer's return

NCT ID NCT06761846

Summary

This study is testing whether adding an immunotherapy drug (sintilimab) to standard chemotherapy after surgery helps prevent stomach or esophageal junction cancer from coming back. It will involve about 70 adults with stage III cancer who have already had surgery to remove their tumor. The main goal is to see if this combination treatment helps patients live longer without their cancer returning.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Hodpital, Chinese Academy of Medical Sciences and Peking Union Medical College

    RECRUITING

    Beijing, Beijing Municipality, 100021, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.